When would you consider adding a PCSK9 inhibitor?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

When would you consider adding a PCSK9 inhibitor?

PCSK9 inhibitors are added when patients at high cardiovascular risk do not reach their LDL-C goals despite maximally tolerated statin therapy (usually with ezetimibe) or when a patient cannot tolerate statins and has high LDL-C. These agents provide substantial further LDL-C reductions beyond what statins can achieve, which is especially important for those with ASCVD or high-risk primary prevention where goals are set lower. They are not intended for all patients regardless of LDL-C, nor are they specifically tied to triglyceride levels. They are considered in statin-intolerant individuals with persistently high LDL-C or in those who remain above goal on combination statin plus ezetimibe.

PCSK9 inhibitors are added when patients at high cardiovascular risk do not reach their LDL-C goals despite maximally tolerated statin therapy (usually with ezetimibe) or when a patient cannot tolerate statins and has high LDL-C. These agents provide substantial further LDL-C reductions beyond what statins can achieve, which is especially important for those with ASCVD or high-risk primary prevention where goals are set lower. They are not intended for all patients regardless of LDL-C, nor are they specifically tied to triglyceride levels. They are considered in statin-intolerant individuals with persistently high LDL-C or in those who remain above goal on combination statin plus ezetimibe.

More practice questions